Companies Dominating the Adenovirus Based Virotherapy Market
- Amgen Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merck & Co., Inc.
- Novartis International AG
- Johnson & Johnson
- Genelux Corporation
- PsiOxus Therapeutics
- Oncorus, Inc.
- SillaJen, Inc.
- Transgene SA
- Virttu Biologics Limited
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of adenovirus based virotherapy is evaluated at USD 14.5 billion.
The adenovirus based virotherapy market size was over USD 13.82 billion in 2024 and is projected to reach USD 28.76 billion by 2037, witnessing around 5.8% CAGR during the forecast period i.e., between 2025-2037. Increasing demand for healthcare sector will fuel the market growth.
Asia Pacific industry is poised to hold largest revenue share of 38% by 2037, impelled by transformative shift in cancer therapeutics in the region.
The major players in the market are Amgen Inc., Merck & Co., Inc., Novartis International AG, Johnson & Johnson, Genelux Corporation, PsiOxus Therapeutics, Oncorus, Inc., and others.
